Cascading Attrition of In Vivo CAR-T Therapy: From Systemic Delivery Failure to Functional Collapse

Area of Science:

• Biotechnology
• Immunotherapy
• Synthetic Biology

Background:

• Ex vivo CAR-T cell therapy shows efficacy but faces manufacturing challenges.
• In vivo reprogramming of T cells is a promising scalable alternative but suffers from efficacy loss.
• Understanding barriers to in vivo T cell engineering is crucial for clinical translation.

Purpose of the Study:

• To review the challenges and barriers limiting in vivo CAR-T cell therapy.
• To compare different delivery platforms like lentiviral vectors and lipid nanoparticles.
• To highlight the potential of synthetic biology for overcoming in vivo delivery hurdles.

Main Methods:

• Review of existing literature on CAR-T cell therapy and in vivo delivery systems.
• Comparative analysis of lentiviral vectors and lipid nanoparticles in navigating physiological barriers.
• Examination of synthetic biology tools for enhancing T cell navigation and function.

Main Results:

• Identified cascading loss of functional vector dose across physiological barriers (e.g., opsonization, metabolic checkpoints).
• Demonstrated that both lentiviral vectors and lipid nanoparticles face distinct challenges in vivo.
• Highlighted that deterministic design with synthetic biology tools is key to overcoming stochastic failure cascades.

Conclusions:

• Overcoming in vivo delivery barriers requires deterministic design integrating synthetic biology.
• Engineered resilience, not just dose escalation, is essential for successful in vivo CAR-T generation.
• This approach transforms in vivo CAR-T generation into a viable platform for treating hematologic malignancies, solid tumors, and autoimmune diseases.